<DOC>
	<DOCNO>NCT00793871</DOCNO>
	<brief_summary>To investigate safety efficacy single agent sunitinib malate Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor .</brief_summary>
	<brief_title>Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologicallyproven diagnosis malignant GIST ( Gastrointestinal Stromal Tumors ) . Evidence unidimensionally measurable disease Failure prior treatment imatinib intolerant imatinib Male female , 18 year age old . ECOG ( Eastern Cooperative Oncology Group ) performance status 0 1 . Resolution acute toxic effect Adequate organ function . Anticancer treatment last dose imatinib Major surgery within 4 week radiation therapy within 2 week . Grade 3 hemorrhage within 4 week prior start study treatment . Diagnosis second malignancy within last 5 year . History brain disease . Cardiac disease within 12 month . Thyroid function abnormality . Ongoing cardiac dysrhythmias . Uncontrolled hypertension . Ongoing treatment anticoagulant CYP3A4 inhibitor inducer . HIV AIDS relate illness . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>sunitinib</keyword>
	<keyword>Phase IV</keyword>
	<keyword>gastrointestinal stomal tumor</keyword>
	<keyword>imatinib resistant intolerant</keyword>
	<keyword>Chinese</keyword>
</DOC>